Amylyx Augments Case for ALS Drug Ahead of PDUFA Date

Shares of Amylyx Pharmaceuticals are falling again, despite the company announcing positive long-term survival analysis data for AMX0035, its experimental amyotrophic lateral sclerosis (ALS) therapy that is up for potential approval from the U.S. Food and Drug Administration next month.